Overview Dividends

(CME) CME - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US12572Q1058

Futures, Options, Swaps, Clearing, Data

CME EPS (Earnings per Share)

EPS Growth (3Y CAGR): -54.66%
EPS Trend (3Y Correlation): -30.3%

CME Revenue

Revenue Growth (3Y CAGR): 12.37%
Revenue Trend (3Y Correlation): 93.3%

Description: CME CME September 25, 2025

CME Group Inc. (NASDAQ:CME) operates a global network of futures and options exchanges, offering contracts on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, metals, as well as fixed-income and currency trading services. Its business also includes clearing-house functions-settling, guaranteeing, and risk-mitigating futures, options, and cleared swaps-plus a suite of real-time and historical market-data products.

According to the 2023 annual report (the most recent publicly available filing), CME generated $5.5 billion in net revenue, with an average daily trading volume of roughly 30 million contracts and cleared-trade value exceeding $30 trillion. The firm holds an estimated 30 percent share of U.S. futures market volume, a position that is reinforced by its dominant role in interest-rate futures-a segment that typically expands when monetary-policy uncertainty rises.

The company’s client base spans professional traders, banks, asset managers, corporations, producers, and sovereign entities, including central banks. Its diversified product set makes it a bellwether for macro-economic shifts: for example, rising Treasury-yield volatility tends to boost demand for CME’s interest-rate futures, while commodity-price spikes drive higher activity in agricultural and energy contracts.

For a data-driven deep-dive into CME’s valuation metrics and scenario analyses, you might find the research tools on ValueRay worth exploring.

CME Stock Overview

Market Cap in USD	96,558m
Sub-Industry	Financial Exchanges & Data
IPO / Inception	2002-12-06

CME Stock Ratings

Growth Rating	85.8%
Fundamental	76.6%
Dividend Rating	76.9%
Return 12m vs S&P 500	6.74%
Analyst Rating	3.39 of 5

CME Dividends

Dividend Yield 12m	4.00%
Yield on Cost 5y	8.19%
Annual Growth 5y	15.22%
Payout Consistency	95.5%
Payout Ratio	87.1%

CME Growth Ratios

Growth Correlation 3m	-58.2%
Growth Correlation 12m	79.3%
Growth Correlation 5y	74.7%
CAGR 5y	21.65%
CAGR/Max DD 3y (Calmar Ratio)	1.86
CAGR/Mean DD 3y (Pain Ratio)	6.27
Sharpe Ratio 12m	2.07
Alpha	13.45
Beta	0.427
Volatility	17.31%
Current Volume	2070.1k
Average Volume 20d	1779.9k
Stop Loss	259.7 (-3%)
Signal	0.41

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (3.76b TTM) > 0 and > 6% of Revenue (6% = 386.6m TTM)

FCFTA 0.02 (>2.0%) and ΔFCFTA -0.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 41.21% (prev 30.61%; Δ 10.60pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.02 (>3.0%) and CFO 4.20b > Net Income 3.76b (YES >=105%, WARN >=100%)

Net Debt (1.44b) to EBITDA (5.35b) ratio: 0.27 <= 3.0 (WARN <= 3.5)

Current Ratio 1.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (360.3m) change vs 12m ago 0.12% (target <= -2.0% for YES)

Gross Margin 86.53% (prev 85.70%; Δ 0.83pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 4.25% (prev 4.70%; Δ -0.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 30.10 (EBITDA TTM 5.35b / Interest Expense TTM 166.6m) >= 6 (WARN >= 3)

Altman Z'' 0.45

(A) 0.01 = (Total Current Assets 145.45b - Total Current Liabilities 142.79b) / Total Assets 179.91b

(B) 0.03 = Retained Earnings (Balance) 5.25b / Total Assets 179.91b

(D) 0.03 = Book Value of Equity 5.30b / Total Liabilities 152.17b

Total Rating: 0.45 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 76.64

1. Piotroski 4.0pt = -1.0

2. FCF Yield 4.20% = 2.10

3. FCF Margin 63.74% = 7.50

4. Debt/Equity 0.12 = 2.49

5. Debt/Ebitda 0.27 = 2.44

6. ROIC - WACC (= 5.19)% = 6.48

7. RoE 13.72% = 1.14

8. Rev. Trend 93.25% = 6.99

9. EPS Trend -30.32% = -1.52

What is the price of CME shares?

As of October 24, 2025, the stock is trading at USD 267.81 with a total of 2,070,083 shares traded.
Over the past week, the price has changed by -0.13%, over one month by +2.58%, over three months by -2.02% and over the past year by +23.69%.

Is CME a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, CME (NASDAQ:CME) is currently (October 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 76.64 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CME is around 289.28 USD . This means that CME is currently overvalued and has a potential downside of 8.02%.

Is CME a buy, sell or hold?

CME has received a consensus analysts rating of 3.39. Therefor, it is recommend to hold CME.

Strong Buy: 4
Buy: 3
Hold: 7
Sell: 4
Strong Sell: 0

What are the forecasts/targets for the CME price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	282.6	5.5%
Analysts Target Price	282.6	5.5%
ValueRay Target Price	319.3	19.2%

CME Fundamental Data Overview October 20, 2025

Market Cap USD = 96.56b (96.56b USD * 1.0 USD.USD)
P/E Trailing = 25.9125
P/E Forward = 22.779
P/S = 15.0106
P/B = 3.4484
P/EG = 5.589
Beta = 0.427
Revenue TTM = 6.44b USD
EBIT TTM = 5.02b USD
EBITDA TTM = 5.35b USD
Long Term Debt = 3.42b USD (from longTermDebt, last quarter)
Short Term Debt = 749.8m USD (from shortTermDebt, last fiscal year)
Debt = 3.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.44b USD (from netDebt column, last quarter)
Enterprise Value = 97.88b USD (96.56b + Debt 3.42b - CCE 2.10b)
Interest Coverage Ratio = 30.10 (Ebit TTM 5.02b / Interest Expense TTM 166.6m)
FCF Yield = 4.20% (FCF TTM 4.11b / Enterprise Value 97.88b)
FCF Margin = 63.74% (FCF TTM 4.11b / Revenue TTM 6.44b)
Net Margin = 58.28% (Net Income TTM 3.76b / Revenue TTM 6.44b)
Gross Margin = 86.53% ((Revenue TTM 6.44b - Cost of Revenue TTM 867.9m) / Revenue TTM)
Gross Margin QoQ = 86.90% (prev 87.41%)
Tobins Q-Ratio = 0.54 (Enterprise Value 97.88b / Total Assets 179.91b)
Interest Expense / Debt = 1.29% (Interest Expense 44.0m / Debt 3.42b)
Taxrate = 22.94% (305.2m / 1.33b)
NOPAT = 3.86b (EBIT 5.02b * (1 - 22.94%))
Current Ratio = 1.02 (Total Current Assets 145.45b / Total Current Liabilities 142.79b)
Debt / Equity = 0.12 (Debt 3.42b / totalStockholderEquity, last quarter 27.74b)
Debt / EBITDA = 0.27 (Net Debt 1.44b / EBITDA 5.35b)
Debt / FCF = 0.35 (Net Debt 1.44b / FCF TTM 4.11b)
Total Stockholder Equity = 27.37b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.09% (Net Income 3.76b / Total Assets 179.91b)
RoE = 13.72% (Net Income TTM 3.76b / Total Stockholder Equity 27.37b)
RoCE = 16.29% (EBIT 5.02b / Capital Employed (Equity 27.37b + L.T.Debt 3.42b))
RoIC = 12.55% (NOPAT 3.86b / Invested Capital 30.79b)
WACC = 7.36% (E(96.56b)/V(99.98b) * Re(7.59%) + D(3.42b)/V(99.98b) * Rd(1.29%) * (1-Tc(0.23)))
Discount Rate = 7.59% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.08%
[DCF Debug] Terminal Value 80.02% ; FCFE base≈3.86b ; Y1≈4.38b ; Y5≈5.99b
Fair Price DCF = 287.7 (DCF Value 103.69b / Shares Outstanding 360.4m; 5y FCF grow 15.74% → 3.0% )
EPS Correlation: -30.32 | EPS CAGR: -54.66% | SUE: -4.0 | # QB: 0
Revenue Correlation: 93.25 | Revenue CAGR: 12.37% | SUE: 0.61 | # QB: 0

Additional Sources for CME Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle